Adjuvants are indispensable components of vaccines for stimulating optimal immune
responses to non-replicating, inactivated and subunit antigens. Eliciting balanced humoral …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …

A fundamental challenge in vaccinology is learning how to induce durable antibody
responses. Live viral vaccines induce antibody responses that last a lifetime, but those …

Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg)
were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with …

HPV infection with 'high-risk'genotypes is associated with ano-genital and oropharyngeal
cancers. Two currently licensed prophylactic HPV vaccines designed to prevent disease …

This study assessed long-term immunogenicity and safety following 3 doses of AS04-
adjuvanted human papillomavirus (HPV)-16/18 L1 virus-like particle (VLP) vaccine in …

Highlights•Reverse, structural and synthetic vaccinology to accelerate novel vaccine
design.•Systems analysis of multiparametric data to predict reactogenicity and …

It is thought that the development of vaccines for the treatment of infectious diseases and
cancer is likely to be achieved in the coming decades. This is partially due to a better …

Annual vaccination is not effective in conferring cross-protection against antigenically
different influenza viruses. Therefore, it is of high priority to improve the cross protective …

Human papillomavirus (HPV) affects hundreds of millions of people worldwide and is
associated with both benign and malignant neoplasms in men and women. It is a double …